CAREDX, INC.
CareDx, Inc. (CDNA)
Overview
CareDx is a Brisbane, California-headquartered precision-medicine company focused entirely on transplant patients, with additional operations in Omaha, Nebraska and Stockholm, Sweden. Trading on Nasdaq under CDNA, the company has had a strong run, with market capitalization reaching about $2.78 billion by September 2026 (up roughly 266% over the prior year) on trailing-twelve-month revenue of $458 million, up 34% year over year. Second-quarter 2026 revenue of $132 million beat consensus of $114 million, prompting management to raise full-year 2026 guidance to $490–$500 million from a prior $447–$465 million range, helped by the completed acquisition of Naveris (maker of the NavDx test) and a favorable finalized Medicare Local Coverage Determination for molecular rejection testing in solid-organ transplants. The company employs about 761 full-time staff across manufacturing, R&D, sales/marketing, and administration.
What They Do & How They Make Money
CareDx makes money primarily through testing services: non-invasive, molecular blood tests that monitor transplant patients for organ rejection and infection risk, which the company performed roughly 200,000 times commercially in 2025. Its flagship AlloSure line (donor-derived cell-free DNA testing for kidney, heart, and lung transplants) is often paired with AlloMap Heart, a gene-expression profiling test, into a combined HeartCare offering; AlloHeme extends the underlying technology to relapse monitoring in leukemia and MDS patients, and AlloCell supports pharmacokinetic monitoring in cell therapy. Medicare accounts for about 46% of testing revenue. Beyond testing, CareDx sells laboratory products — HLA typing kits (QTYPE, Olerup SSP) and NGS-based AlloSeq products — to transplant labs globally, and it runs a digital and patient-solutions business built around its Ottr workflow-management software, used in more than 170 U.S. transplant centers, plus referral management, adherence tracking, and specialty pharmacy services for transplant patients. The company's stated strategy is "solutions-selling" — bundling testing, software, and pharmacy services into concentrated transplant-center relationships to lower customer-acquisition costs and deepen account penetration, then extending into adjacent markets like specialty oncology through the Naveris deal.
Competitors
CareDx names Natera, Eurofins Transplant Genomics, Devyser Diagnostics, and iMDx as competitors in molecular transplant diagnostics, while Thermo Fisher Scientific is identified as the dominant player in HLA typing, an adjacent lab-products category where CareDx also competes.
Competitive Position
CareDx's moat rests on being the first-mover and now-entrenched standard-of-care diagnostics provider across essentially the entire transplant patient journey — a narrow but deep niche where switching an established monitoring protocol carries real clinical and reimbursement risk for a transplant center. The recently finalized Medicare LCD for molecular rejection testing reinforces this by codifying reimbursement around the company's test category, and its Ottr software footprint in 170+ centers creates workflow lock-in that is hard for a single-product competitor to dislodge. The bundled testing-plus-software-plus-pharmacy model raises genuine switching costs once a transplant program has standardized on CareDx, and the company's scale (200,000 tests annually) supports a data and clinical-evidence advantage that newer entrants like Natera's transplant offerings must still build. Risks include continued reliance on Medicare policy, competitive pressure from well-capitalized diagnostics players entering the same niche, and execution risk integrating Naveris into a new oncology vertical. But with revenue growth accelerating, guidance being raised mid-year, and a business built around recurring, clinically necessary monitoring rather than one-time tests, CareDx looks like one of the stronger competitive positions in this cohort.